Biopharmaceutical company ANI Pharmaceuticals Inc (Nasdaq:ANIP) said on Tuesday that it has completed the buyout of its 3.125% perpetual royalty obligation to SWK Funding LLC (SWK) on worldwide net revenues from ILUVIEN and YUTIQ.
The one-time payment of USD17.25m eliminates the royalty obligation, effective from 1 January 2025.
The buyout was funded using ANI's cash on hand. This transaction is part of ANI's strategy to strengthen its Retina portfolio and maximise the long-term value of ILUVIEN and YUTIQ.
Nikhil Lalwani, president and CEO of ANI, emphasized that this move enhances the company's financial flexibility and supports its goal of accelerating growth and improving patient outcomes.
Bavarian Nordic sells US Priority Review Voucher for USD160m
FDA grants priority review to Innoviva's zoliflodacin for treatment of gonorrhea
Sanofi to acquire Blueprint Medicines in USD9.5bn rare disease deal
Eisai forecasts 73% Leqembi revenue growth in FY 2025, boosting BioArctic royalties
ValiRx subsidiary Inaphaea extends drug repurposing deal with Dominion Biotech
Lilly declares Q2 2025 dividend
Bruker acquires majority stake in RECIPE to expand clinical mass spectrometry diagnostics
Emmaus Life Sciences reports drop in revenues, increased loss in 2024
L'Oréal and WHO Foundation partner to expand global skin health access